Article

2 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 62, n° 3
pages 418-426 (mars 2010)
Doi : 10.1016/j.jaad.2009.03.014
accepted : 12 Mars 2009
Original Articles

Folliculotropic mycosis fungoides: Clinicopathological features and outcome in a series of 20 cases
 

Cristina Muniesa, MD a, Teresa Estrach, MD b, Ramon M. Pujol, MD c, Fernando Gallardo, MD c, Pilar Garcia-Muret, MD d, Josefina Climent, MD e, Octavio Servitje, MD a,
a Department of Dermatology, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain 
e Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain 
b Department of Dermatology at Hospital Clínic, IDIBAPS, Barcelona, Spain 
c Department of Dermatology, Hospital del Mar, IMAS, Barcelona, Spain 
d Department of Dermatology, Hospital de Sant Pau, Barcelona, Spain 

Correspondence to: Octavio Servitje, MD, Department of Dermatology, Hospital Universitari de Bellvitge, c/Feixa Llarga s/n, ĹHospitalet de Llobregat, 08907-Barcelona, Spain.
Abstract
Background

Folliculotropic mycosis fungoides (MF) is a rare variant of cutaneous T-cell lymphoma in which the neoplastic T lymphocytes display tropism for the follicular epithelium.

Objectives

To better categorize this rare form of cutaneous T-cell lymphoma we evaluated the clinical, pathological, and immunophenotypic findings, and the response to therapy and course of the disease.

Methods

Folliculotropic MF cases were selected from the registry of the Thematic Network of Cutaneous Lymphoma of Barcelona (Spain) from 1988 to 2007.

Results

Twenty patients (11 male, 9 female) with a mean age of 54 years were included. Mean follow-up time was 43 months. The most common sites of involvement were the head and neck (80%), upper extremities, and thorax. Infiltrated plaques (55%), acneiform lesions (comedo-like and epidermal cysts) (45%), and follicular keratosis-pilaris–like lesions (45%) were the more prominent features. Histopathological findings included selective infiltration of the follicular epithelium by atypical lymphocytes in all cases. Mucinous degeneration of the follicular epithelium occurred in 60% of cases. Psoralen plus ultraviolet A therapy was the treatment of choice in the majority of patients, but these patients did not respond as well as patients with classic MF. Radiotherapy (local or total skin electron beam) was found to be the most effective treatment. A good response to bexarotene was seen in some patients.

Limitation

This was a case series descriptive study.

Conclusions

Folliculotropic MF is a rare but well-defined clinicopathological variant of MF. Although refractory to standard therapies used in classic MF, most of our patients showed only slow disease progression.

The full text of this article is available in PDF format.

Key words : cutaneous T-cell lymphoma, folliculotropic mycosis fungoides, mycosis fungoides

Abbreviations used : CTCL, MF, TSEB, UV



 Supported by Fondo de Investigación Sanitaria (FIS) grant PI050458.
 Conflicts of interest: None declared.
 Reprints not available from the authors.



© 2010  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline